<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(1)</volume><submitter>Lockbaum GJ</submitter><pubmed_abstract>XRN1 (5'-3' exoribonuclease 1) degrades RNA from the 5' → 3' direction and utilizes both single- and double-stranded RNA as substrates. XRN1 plays a critical role in mRNA turnover as well as regulating the cellular response to viral infection. XRN1 also protects the cell by preventing endogenous double-stranded RNA accumulation. XRN1 was identified as a putative vulnerability in a subset of cancer cell lines through analysis of publicly available CRISPR data. The role of XRN1 was explored using a set of non-small cell lung cancer cell lines with differential predicted XRN1 dependency to validate XRN1 as an oncology target. In predicted sensitive cell lines, XRN1 knockout reduced proliferation, increased apoptosis and activated the pPKR and MDA5 dsRNA sensing pathways. To facilitate drug di</pubmed_abstract><journal>Communications biology</journal><pagination>589</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11982291</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3',5'-bisphosphate as a potent enzyme inhibitor.</pubmed_title><pmcid>PMC11982291</pmcid><pubmed_authors>Wu J</pubmed_authors><pubmed_authors>Silver SJ</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Blakemore SJ</pubmed_authors><pubmed_authors>Sickmier EA</pubmed_authors><pubmed_authors>Duncan KW</pubmed_authors><pubmed_authors>Shehaj L</pubmed_authors><pubmed_authors>Yao S</pubmed_authors><pubmed_authors>Ribich S</pubmed_authors><pubmed_authors>Shen SA</pubmed_authors><pubmed_authors>Case A</pubmed_authors><pubmed_authors>Lynes MM</pubmed_authors><pubmed_authors>Buker SM</pubmed_authors><pubmed_authors>Holt N</pubmed_authors><pubmed_authors>Boriack-Sjodin PA</pubmed_authors><pubmed_authors>Nayak SP</pubmed_authors><pubmed_authors>Lockbaum GJ</pubmed_authors><pubmed_authors>Grigoriu S</pubmed_authors><pubmed_authors>Sparling BA</pubmed_authors><pubmed_authors>Knockenhauer KE</pubmed_authors><pubmed_authors>Raman A</pubmed_authors><pubmed_authors>Copeland RA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3',5'-bisphosphate as a potent enzyme inhibitor.</name><description>XRN1 (5'-3' exoribonuclease 1) degrades RNA from the 5' → 3' direction and utilizes both single- and double-stranded RNA as substrates. XRN1 plays a critical role in mRNA turnover as well as regulating the cellular response to viral infection. XRN1 also protects the cell by preventing endogenous double-stranded RNA accumulation. XRN1 was identified as a putative vulnerability in a subset of cancer cell lines through analysis of publicly available CRISPR data. The role of XRN1 was explored using a set of non-small cell lung cancer cell lines with differential predicted XRN1 dependency to validate XRN1 as an oncology target. In predicted sensitive cell lines, XRN1 knockout reduced proliferation, increased apoptosis and activated the pPKR and MDA5 dsRNA sensing pathways. To facilitate drug di</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Apr</publication><modification>2026-06-01T17:57:01.505Z</modification><creation>2025-07-14T03:02:39.114Z</creation></dates><accession>S-EPMC11982291</accession><cross_references><pubmed>40205031</pubmed><doi>10.1038/s42003-025-08005-y</doi></cross_references></HashMap>